secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zenas BioPharma, Inc. (ZBIO)
CIK:        0001953926
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001104659-25-076464
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zenas BioPharma Q2 net loss $52.2M; cash $274.9M; obexelimab trials on track
----------------------------------------------------------------------------

- Net loss of $52.2M for Q2 2025, compared to $38.0M in Q2 2024.
- Cash, cash equivalents and investments of $274.9M as of June 30, 2025; expected runway into Q4 2026.
- Phase 3 INDIGO trial (IgG4-RD) topline results expected around year-end 2025.
- Phase 2 MoonStone trial (RMS) enrollment completed; results early Q4 2025.
- Phase 2 SunStone trial (SLE) enrollment expected by year-end 2025; topline mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/0001104659-25-076464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-076464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer